BioNTech says dual-acting lung cancer drug helped shrink tumors

The Bristol Myers-partnered bispecific antibody kept small cell lung cancer under control in participants enrolled in a Phase 2 trial.

Jonathan Gardner Member since November 15, 2023

Loading + Follow Following